课题基金 / 基金详情

Dysregulated fat utilization in diabetic cardiomyopathy

Dysregulated fat utilization in diabetic cardiomyopathy
糖尿病心肌病中脂肪利用失调
批准号:
6340519
负责人:
Brian N Finck
金额:
$3.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
未结题
起止时间:
2001-06-01 至

项目摘要

项目成果

Brian N Finck的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Applicant?s abstract): Cardiac dysfunction occurs at a higher rate in patients with diabetes mellitus, even when risk factors, like coronary artery disease, are accounted for. This proposal is designed to test the hypothesis that excessive rates of myocardial fatty acid uptake and oxidation lead to pathologic remodeling similar to that in diabetic cardiomyopathy. To this end, we have focused on the peroxisome proliferator-activated receptor a (PPARa), a nuclear receptor transcription factor that activates cardiac fatty acid (FA) utilization pathways. Transgenic mice that over-express PPARa in a cardiac-specific manner (MHC-PPARa mice) have been generated. Because PPARa plays a critical role in regulating the expression of genes encoding cellular FA utilization enzymes, it is predicted that rates of FA import and oxidation will be increased in the hearts of MHC-PPARa mice, which in turn may lead to cardiac hypertrophy, dysfunction and ultimately failure. The specific aims of this proposal are 1) To characterize the metabolic phenotype of MHC-PPARa mice. 2) To characterize cardiac structure and function in MHC-PPARa mice. 3) To compare the myocardial phenotype of MHC-PPARa mice to the streptozotocin-induced model of diabetic cardiomyopathy and to determine the role of altered substrate utilization in the genesis and severity of cardiac dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phenomaster NG Mouse Metabolic Phenotyping System
  • 批准号:
    10427654
  • 项目类别:
  • 资助金额:
    $52.37万
  • 财政年份:
    2022
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10218153
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10096091
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10471836
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位: